|

Product Pipeline
|
Programs Under Development |
Branded Products (a) |
Therapeutic
Category |
NDA / ANDA |
Development Stage (b) |
Partnered |
ELI-154
Oxycodone CR
Once a day |
NA |
Pain |
NDA |
Phase III pending |
No |
ELI-216
Abuse Resistance Product for use with
oxycodone or other opioids |
N/A |
Pain |
NDA |
Phase III pending |
No |
|
Undisclosed Twice a day |
Undisclosed |
Anti-infective |
ANDA |
Pilot BE study complete |
No |
|
Undisclosed Once a day |
Undisclosed |
Gastrointestinal |
ANDA
|
Pilot BE study complete |
Yes |
|
Commercial
Products |
|
Commercial
Product |
Branded Products (a) |
Therapeutic
Category |
Commercial
Status |
Partner |
|
Lodrane® Once a Day |
N/A |
Allergy |
Launched |
ECR Pharmaceuticals |
|
Lodrane 24D ® Once a day |
N/A |
Allergy |
Launched |
ECR Pharmaceuticals |
|
Methadone Hydrochloride
10 mg tablets |
Dolophine®
hydrochloride, 10 mg tablets |
Pain |
FDA Approved, Launch pending |
ThePharmaNetwork |
(a) The name of our
competitor’s branded product. N/A
(b) Preclinical testing refers to
studies done before initiation of any human studies. Pilot Phase I studies for
the NDA products are generally preliminary studies done in healthy human
subjects to assess the tolerance/safety and pharmacokinetics (PK) of the
product. Additional larger studies in humans will be required prior to
submission of this product to the FDA for review. Pilot bioequivalence (BE)
studies are initial studies done in humans for generic products and are used to
assess the likelihood of achieving bioequivalence for generic products. Larger
pivotal bioequivalence studies will be required prior to submission of the
product for FDA for review.
|